We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

141 hedge funds and large institutions have $843M invested in CytomX Therapeutics in 2018 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 42 increasing their positions, 43 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,438% more call options, than puts

Call options by funds: $2.72M | Put options by funds: $177K

160% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 15

32% more capital invested

Capital invested by funds: $637M → $843M (+$206M)

18% more funds holding

Funds holding: 119 → 141 (+22)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 43

1.44% less ownership

Funds ownership: 78.49% → 77.05% (-1.4%)

Holders
141
Holders Change
+22
Holders Change %
+18.49%
% of All Funds
3.23%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
39
Increased
42
Reduced
43
Closed
15
Calls
$2.72M
Puts
$177K
Net Calls
+$2.55M
Net Calls Change
+$2.58M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$69.7M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$10.5M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$7.5M
4
Renaissance Technologies
Renaissance Technologies
New York
+$7.02M
5
PC
PointState Capital
New York
+$4.4M

Top Sellers

Rank Fund Capital Flow
1
TG
TRV GP
Massachusetts
-$65.6M
2
BI
BVF Inc
California
-$23.7M
3
PA
Perceptive Advisors
New York
-$8.04M
4
Millennium Management
Millennium Management
New York
-$6.92M
5
PAG
Private Advisor Group
New Jersey
-$4.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
51
Wells Fargo
California
$1.7M -$2.35M -82,353 -58%
Allianz Asset Management
52
Allianz Asset Management
Germany
$1.67M +$115K +4,036 +7%
USAA
53
United Services Automobile Association
Texas
$1.53M +$721K +25,261 +88%
Ameriprise
54
Ameriprise
Minnesota
$1.5M +$1.51M +52,793 New
EGI
55
EAM Global Investors
California
$1.38M +$1.39M +48,575 New
CS
56
Credit Suisse
Switzerland
$1.35M +$415K +14,549 +44%
Citadel Advisors
57
Citadel Advisors
Florida
$1.34M +$1.34M +47,016 New
New York State Common Retirement Fund
58
New York State Common Retirement Fund
New York
$1.33M +$126K +4,420 +10%
UBS Group
59
UBS Group
Switzerland
$1.31M +$992K +34,767 +311%
AQR Capital Management
60
AQR Capital Management
Connecticut
$1.3M -$1.42M -49,675 -52%
JG
61
Jefferies Group
New York
$1.29M +$1.29M +45,214 New
California State Teachers Retirement System (CalSTRS)
62
California State Teachers Retirement System (CalSTRS)
California
$1.26M -$44.3K -1,551 -3%
TD Asset Management
63
TD Asset Management
Ontario, Canada
$1.24M +$1.24M +43,500 New
SCA
64
Secor Capital Advisors
New York
$1.23M +$1.23M +43,228 New
EI
65
EAM Investors
California
$1.22M +$1.23M +42,990 New
Bank of Montreal
66
Bank of Montreal
Ontario, Canada
$1.22M +$1.06M +37,083 +636%
Schroder Investment Management Group
67
Schroder Investment Management Group
United Kingdom
$1.21M -$1.05M -36,891 -46%
FP
68
Foundry Partners
Minnesota
$1.21M -$2.8K -98 -0.2%
CS
69
Candriam SCA
Luxembourg
$1.17M -$1.37M -48,000 -54%
SCM
70
Sterling Capital Management
North Carolina
$1.07M – – –
Swiss National Bank
71
Swiss National Bank
Switzerland
$1.01M +$62.8K +2,200 +7%
VEA
72
Virtus ETF Advisers
New York
$992K +$537K +18,817 +117%
Citigroup
73
Citigroup
New York
$902K -$174K -6,104 -16%
RhumbLine Advisers
74
RhumbLine Advisers
Massachusetts
$824K +$5.71K +200 +0.7%
AIM
75
Assured Investment Management
New York
$819K +$822K +28,793 New
1 2
3
4 5

CTMX Hedge Fund Activity: Q1 2018 in Review

141 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2018, worth a combined $843M — up 32% from $637M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new CTMX positions and 15 closed out — a net gain of 24 holders — while 42 added to existing stakes and 43 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $69.7M. The largest seller was TRV GP, cutting an estimated $65.6M.

  • 141 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2018, up from 119 in Q4 2017.
  • Funds reported $843M of CytomX Therapeutics stock for Q1 2018, up 32% quarter-over-quarter.
  • 39 funds opened new CytomX Therapeutics positions in Q1 2018 and 15 closed out, a net change of +24 holders.
  • The largest CytomX Therapeutics buyer in Q1 2018 was T. Rowe Price Associates, an estimated $69.7M added.
  • The largest CytomX Therapeutics seller in Q1 2018 was TRV GP, an estimated $65.6M sold.

Based on aggregated 13F filings for Q1 2018.